Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) rose 6.5% during mid-day trading on Thursday . The stock traded as high as $7.17 and last traded at $6.73. Approximately 77,926 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 85,513 shares. The stock had previously closed at $6.32.
Analyst Ratings Changes
AVTX has been the topic of several recent research reports. BTIG Research initiated coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $40.00 price target on the stock. HC Wainwright initiated coverage on shares of Avalo Therapeutics in a research note on Thursday, October 24th. They issued a "neutral" rating on the stock.
View Our Latest Research Report on Avalo Therapeutics
Avalo Therapeutics Price Performance
The firm's 50 day simple moving average is $9.42 and its 200-day simple moving average is $10.18.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of AVTX. Affinity Asset Advisors LLC increased its stake in shares of Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company's stock worth $561,000 after purchasing an additional 35,000 shares during the last quarter. Logos Global Management LP acquired a new position in shares of Avalo Therapeutics during the 2nd quarter worth about $6,722,000. Ikarian Capital LLC increased its stake in shares of Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company's stock worth $9,218,000 after purchasing an additional 915,629 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new position in shares of Avalo Therapeutics during the 3rd quarter worth about $9,186,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Recommended Stories
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
